 Neurotrope, Inc. Nasdaq: NTRP Neurotrope or the Company today announced its entry into a strategic agreement with BryoLogyx Inc., for the supply of synthetic, GMP-certified Bryostatin-1, manufactured by Albany Molecular Research, Inc. AMRI, a leading global CDMO provider of advanced drug development and manufacturing solutions. Neurotrope expects to use the synthetic Bryostatin-1 in its clinical development initiatives aimed at advancing its lead product candidate for the treatment of Alzheimers disease AD and other neurodegenerative diseases and, ultimately, as a source for potential commercial drug supply if regulatory approval is received. 